Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-27
2007-03-27
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S575000, C540S115000, C514S233200, C514S228500, C514S259300, C544S281000, C544S117000, C544S061000
Reexamination Certificate
active
11245401
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5571813 (1996-11-01), Rühter et al.
patent: 5602136 (1997-02-01), Rühter et al.
patent: 5602137 (1997-02-01), Rühter et al.
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6107305 (2000-08-01), Misra et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6313124 (2001-11-01), He et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 2005/0222171 (2005-10-01), Bold et al.
patent: 2006/0053568 (2006-03-01), Fadli
patent: 2006/0135526 (2006-06-01), Clasby et al.
patent: 102 23 917 (2003-11-01), None
patent: 0 628 559 (2002-04-01), None
patent: 1 334 973 (2003-08-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 01/23388 (2001-04-01), None
patent: WO 02/22610 (2002-03-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 03/091256 (2003-11-01), None
patent: WO 03/095455 (2003-11-01), None
patent: WO 2004/081013 (2004-09-01), None
patent: WO 2004/087707 (2004-10-01), None
patent: WO 2005/027907 (2005-03-01), None
patent: WO 2005/070431 (2005-08-01), None
patent: WO 2006/044958 (2006-04-01), None
Fischer, P.M.; Gianella-Borradori, A.; CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.
Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477.
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem (1994), 224: 771-786.
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”, Journal of Medical Chemistry, (2002), 45: 3905-3927.
Mettey et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects”, J. Med. Chem. (2003), 46(2): 222-236.
Novinson et al., “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines”, J. Med. Chem. (1977), 20(2): 296-299.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms”, Journal of Clinical Oncology (Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”, Eur. J. Biochem. (1997), 243:527-536.
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”, Cancer Research (Aug. 15, 1997) 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-]pyrimidine Derivatives”, Chem. Pharm. Bull. (1999), 47(7): 928-938.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-•]pyrimidine Derivatives”, Chem. Pharm. Bull. (1999), 47(7): 928-938.
Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62).
Yasuo Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-•]pyrimidines.”, Chem. Pharm. Bull (1962), 10: 620-626.
Cai et al., “5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors”, J. Med. Chem. (1997), 40:3679-3686.
Bruce L. Finkelstein, “Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine”, J. Org. Chem., (1992), 57: 5538-5540.
Ongkeko et al., “Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage”, Journal of Cell Science (1995), 108: 2897-2904.
Shiota et al., “Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine”, J. Org. Chem. (1999), 64: 453-457.
Novinson et al., “Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-•s-triazines”, Journal of Medicinal Chemistry, (1976), 19(4): 517-520.
Bullok et al., “Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase”, J. Med. Chem. (Received May 24, 2006)—11pgs.
Ishiharo Sangyo Kaisha, JP2006/160628 Translation—27pgs.
International Search Report for PCT/US2005/003859 mailed Jul. 29, 2006—5pgs.
Dwyer Michael P.
Guzi Timothy J.
Keertikar Kartik M.
Labroli Marc
Paruch Kamil
Berch Mark L.
Kalyanaraman Palaiyur S.
Moore Susanna
Schering Corpoartion
LandOfFree
Trisubstituted and tetrasubstituted pyrazolopyrimidines as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trisubstituted and tetrasubstituted pyrazolopyrimidines as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trisubstituted and tetrasubstituted pyrazolopyrimidines as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730315